Your shopping cart is currently empty

D-GsMTx4 TFA, a selective spider venom peptide, is a TRPC1/6 and Piezo2 inhibitor that inhibits cation-permeable mechanosensitive channels (MSCs) belonging to the Piezo and TRP channel families, blocks cation-selective stretch-activated channels (SACs), and attenuates lysophosphatidylcholine (LPC)-induced astrocyte toxicity and microglia reactivity. toxicity and microglia reactivity.D-GsMTx4 TFA prevented myocardial infarction in a mouse model of ischemia/reperfusion and can be used to characterize the role of excitatory MSCs in normal physiology and pathology.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 500 μg | $438 | In Stock | In Stock | |
| 1 mg | $633 | In Stock | In Stock | |
| 5 mg | $1,320 | In Stock | In Stock | |
| 10 mg | $1,780 | In Stock | In Stock | |
| 25 mg | $2,650 | In Stock | In Stock | |
| 50 mg | $3,570 | In Stock | In Stock |
| Description | D-GsMTx4 TFA, a selective spider venom peptide, is a TRPC1/6 and Piezo2 inhibitor that inhibits cation-permeable mechanosensitive channels (MSCs) belonging to the Piezo and TRP channel families, blocks cation-selective stretch-activated channels (SACs), and attenuates lysophosphatidylcholine (LPC)-induced astrocyte toxicity and microglia reactivity. toxicity and microglia reactivity.D-GsMTx4 TFA prevented myocardial infarction in a mouse model of ischemia/reperfusion and can be used to characterize the role of excitatory MSCs in normal physiology and pathology. |
| Molecular Weight | 4216.93 |
| Formula | C187H279F3N48O48S6 |
| Smiles | [H]NCC(N[C@@H](CS)C(N[C@H](C(N[C@H](C(N[C@@H](CC1=CC=CC=C1)C(N[C@@H](CC2=CNC3=C2C=CC=C3)C(N[C@@H](CC4=CNC5=C4C=CC=C5)C(N[C@H](C(N[C@@H](CS)C(N[C@H](C(N6CCC[C@H]6C(N[C@H](C(N[C@@H](CC(O)=O)C(N[C@@H](CC(O)=O)C(N[C@H](C(N[C@@H](CS)C(N[C@@H](CS)C(N[C@H](C(N7CCC[C@H]7C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@@H](CS)C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@@H](CC8=CC=CC=C8)C(N[C@H](C(N[C@H](C(N[C@@H](CS)C(N[C@H](C(N[C@@H](CC9=CC=CC=C9)C(N[C@H](C(N[C@@H](CC%10=CC=CC=C%10)C(O)=O)=O)CO)=O)=O)CC(N)=O)=O)=O)CC(C)C)=O)CCCCN)=O)=O)CC(C)C)=O)CCCCN)=O)CO)=O)=O)CCCCN)=O)CC(C)C)=O)CCCCN)=O)=O)CCCNC(N)=N)=O)=O)=O)CCCCN)=O)=O)=O)CC(N)=O)=O)=O)CC(N)=O)=O)=O)CCCCN)=O)=O)=O)=O)CCC(O)=O)=O)CC(C)C)=O)=O.OC(C(F)(F)F)=O |
| Relative Density. | no data available |
| Sequence | Gly-Cys-Leu-Glu-Phe-Trp-Trp-Lys-Cys-Asn-Pro-Asn-Asp-Asp-Lys-Cys-Cys-Arg-Pro-Lys-Leu-Lys-Cys-Ser-Lys-Leu-Phe-Lys-Leu-Cys-Asn-Phe-Ser-Phe-NH2 (Disulfide bridge:Cys2-Cys17, Cys9-Cys23, Cys16-Cys30) |
| Sequence Short | GCLEFWWKCNPNDDKCCRPKLKCSKLFKLCNFSF(Modifications: All aminoacids = D-aminoacids, Disulfide bridges: 2-17, 9-23, 16-30, Phe-34 = C-terminal amide) |
| Storage | store at low temperature,keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 250 mg/mL (59.28 mM) H2O: 36 mg/mL (8.54 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+90% Saline: 3.3 mg/mL (0.78 mM), Sonication is recommeded. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
H2O/DMSO
DMSO
| ||||||||||||||||||||||||||||||||||||
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.